2. Immunology/Inflammation
  3. COX
  4. Piroxicam

Piroxicam  (Synonyms: 吡罗昔康; CP-16171)

目录号: HY-B0253 纯度: 99.71%
COA 产品使用指南

摩尔计算器

Piroxicam (CP-16171) 是一种非甾体抗炎剂，能够抑制 COX 的活性，对人单核细胞 COX-1 和 COX-2 的 IC50 值分别为 47 和 25 μM。

MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

Piroxicam Chemical Structure

Piroxicam Chemical Structure

CAS No. : 36322-90-4

1.  客户无需承担相应的运输费用。

2.  同一机构（单位）同一产品试用装仅限申领一次，同一机构（单位）一年内

     可免费申领三个不同产品的试用装。

3.  试用装只面向终端客户。

规格 价格 是否有货 数量
10 mM * 1 mL in DMSO ￥198
In-stock
100 mg ￥180
In-stock
500 mg ￥400
In-stock
1 g ￥500
In-stock
5 g ￥1004
In-stock
10 g ￥1758
In-stock
50 g   询价  

* Please select Quantity before adding items.

Customer Review

Other Forms of Piroxicam:

Piroxicam 相关抗体

Top Publications Citing Use of Products

MCE 顾客使用本产品发表的 1 篇科研文献

查看 COX 亚型特异性产品:

查看所有亚型
COX COX-1 COX-2 COX-3

  • 生物活性

  • 实验参考方法

  • 纯度 & 产品资料

  • 参考文献

生物活性

Piroxicam (CP-16171) is a non-steroidal anti-inflammatory drugs, acts as a COX inhibitor, with IC50s of 47, 25 μM for human monocyte COX-1 and COX-2, respectively.

IC50 & Target[1]

COX-2

25 μM (IC50, in human monocytes)

COX-1

47 μM (IC50, in human monocytes)

细胞效力
(Cellular Effect)
Cell Line Type Value Description References
THP-1 IC50
> 20 μM
Compound: Piroxicam
Antiinflammatory activity in human THP1 cells assessed as inhibition of PMA-induced TNF-alpha secretion incubated for 2 hrs prior to PMA challenge measured after 48 hrs by ELISA
Antiinflammatory activity in human THP1 cells assessed as inhibition of PMA-induced TNF-alpha secretion incubated for 2 hrs prior to PMA challenge measured after 48 hrs by ELISA
[PMID: 24531227]
THP-1 IC50
18 μM
Compound: Piroxicam
Antiinflammatory activity in human THP1 cells assessed as inhibition of PMA-induced IL-1beta secretion preincubated for 2 hrs followed by PMA challenge measured after 48 hrs by ELISA
Antiinflammatory activity in human THP1 cells assessed as inhibition of PMA-induced IL-1beta secretion preincubated for 2 hrs followed by PMA challenge measured after 48 hrs by ELISA
[PMID: 24780595]
THP-1 IC50
18.1 μM
Compound: Piroxicam
Anti-inflammatory activity in human THP1 cells assessed as inhibition of PMA-induced IL-1beta production after 48 hrs by ELISA
Anti-inflammatory activity in human THP1 cells assessed as inhibition of PMA-induced IL-1beta production after 48 hrs by ELISA
[PMID: 26748696]
THP-1 IC50
21.33 μM
Compound: Piroxicam
Antiinflammatory activity in human THP1 cells assessed as inhibition of PMA-induced IL-1beta secretion preincubated for 1 hr prior PMA-challenge measured after 48 hrs by ELISA
Antiinflammatory activity in human THP1 cells assessed as inhibition of PMA-induced IL-1beta secretion preincubated for 1 hr prior PMA-challenge measured after 48 hrs by ELISA
[PMID: 23811092]
体外研究
(In Vitro)

Piroxicam (CP-16171) is a non-steroidal anti-inflammatory drugs, acts as a COX inhibitor, with IC50s of 47, 25 μM for human monocyte COX-1 and COX-2, respectively[1]. Piroxicam (CP-16171) (167, 333, 500 μM) decreases cell population of T24 and the 5637 cells. Piroxicam (CP-16171) (500 μM) also reduces the cell viability of T24 and 5637 cell, and is significantly effective when combined with 0.05 μM carboplatin. The combination also inhibits Ki-67 expression in booth cells[3].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Piroxicam 相关抗体:
体内研究
(In Vivo)

Piroxicam (CP-16171) (0.3 mg/kg qd 24-h p.o.) reduces tumor volume in 12 of 18 dogs, and such and effect is via induction of apoptosis and reduction in urine basic fibroblast growth factor concentration[2].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Clinical Trial
分子量

331.35

Formula

C15H13N3O4S
CAS 号
性状

固体

颜色

Light yellow to yellow

中文名称

吡罗昔康
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 2 years
-20°C 1 year
溶解性数据
细胞实验： 

DMSO 中的溶解度 : 50 mg/mL (150.90 mM; 超声助溶; 吸湿的 DMSO 对产品的溶解度有显著影响，请使用新开封的 DMSO)

H2O 中的溶解度 : < 0.1 mg/mL (insoluble)

配制储备液
浓度 溶剂体积 质量 1 mg 5 mg 10 mg
1 mM 3.0180 mL 15.0898 mL 30.1796 mL
5 mM 0.6036 mL 3.0180 mL 6.0359 mL
查看完整储备液配制表

* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 2 years; -20°C, 1 year。-80°C储存时，请在2年内使用， -20°C储存时，请在1年内使用。

  • 摩尔计算器

  • 稀释计算器

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

质量
=
浓度
×
体积
×
分子量 *

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

浓度 (start)

C1

×
体积 (start)

V1

=
浓度 (final)

C2

×
体积 (final)

V2

动物实验：

请根据您的 实验动物和给药方式 选择适当的溶解方案。

以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：
——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；
以下溶剂前显示的百分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

  • 方案 一

    请依序添加每种溶剂： 10% DMSO    40% PEG300    5% Tween-80    45% Saline

    Solubility: ≥ 2.5 mg/mL (7.54 mM); 澄清溶液

    此方案可获得 ≥ 2.5 mg/mL（饱和度未知）的澄清溶液。

    以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；再向上述体系中加入 50 μL Tween-80，混合均匀；然后再继续加入 450 μL 生理盐水 定容至 1 mL。

    生理盐水的配制：将 0.9 g 氯化钠，溶解于 ddH₂O 并定容至 100 mL，可以得到澄清透明的生理盐水溶液。
  • 方案 二

    请依序添加每种溶剂： 10% DMSO    90% (20% SBE-β-CD in Saline)

    Solubility: ≥ 2.5 mg/mL (7.54 mM); 澄清溶液

    此方案可获得 ≥ 2.5 mg/mL（饱和度未知）的澄清溶液。

    以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液 中，混合均匀。

    2 g SBE-β-CD（磺丁基醚 β-环糊精）粉末定容于 10 mL 的生理盐水中，完全溶解至澄清透明。
动物溶解方案计算器
请输入动物实验的基本信息：

给药剂量

mg/kg

动物的平均体重

g

每只动物的给药体积

μL

动物数量

只
由于实验过程有损耗，建议您多配一只动物的量
请输入您的动物体内配方组成：
%
DMSO +
% 
+
%
Tween-80 +
%
Saline
如果您的动物是免疫缺陷鼠或者体弱鼠，建议 DMSO 中的在最后工作液体系中的占比尽量不超过 2%。
方案所需 助溶剂 包括：DMSO， ，均可在 MCE 网站选购。 ，Tween 80，均可在 MCE 网站选购。
计算结果
工作液所需浓度 : mg/mL
储备液配制方法 : mg 药物溶于 μL  DMSO（母液浓度为 mg/mL）。
您所需的储备液浓度超过该产品的实测溶解度，以下方案仅供参考，如有需要，请与 MCE 中国技术支持联系。
动物实验体内工作液的配制方法 : 取 μL DMSO 储备液，加入 μL 。 μL ，混合均匀至澄清，再加 μL Tween 80，混合均匀至澄清，再加 μL 生理盐水。
连续给药周期超过半月以上，请谨慎选择该方案。
请确保第一步储备液溶解至澄清状态，从左到右依次添加助溶剂。您可采用超声加热 （超声清洗仪，建议频次 20-40 kHz），涡旋吹打等方式辅助溶解。
纯度 & 产品资料
参考文献
Cell Assay
[3]

Urinary bladder cancer cell lines are treated with graded concentrations of carboplatin (0.05, 0.5 and 1 μM) and Piroxicam (CP-16171) (167, 333 and 500 μM) for 72 h to assess dose-response profiles. For the combination approach, 0.05 μM of carboplatin is used with 333 μM Piroxicam. Both drugs are freshly prepared before each experiment. An untreated control group (cells not exposed to carboplatin and Piroxicam) is used for all assays[3].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Animal Administration
[2]

Dogs[2]
Dogs undergo tumor staging, including thoracic and abdominal radiography, cystography, ultrasonography, and cystoscopy (with collection of tissue samples) before treatment and after 4 weeks of Piroxicam (CP-16171) (0.3 mg/kg qd 24-h p. o.) treatment. Dogs receive no other cancer treatment during the 4 weeks of Piroxicam (CP-16171) treatment. Tissue samples are immediately frozen in liquid nitrogen for PGE2 analysis or fixed in 10% neutral buffered formalin for immunohistochemical examination. Urine is also collected before and after Piroxicam treatment, aliquoted, and then stored at −80°C until analyzed[2].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.
参考文献

Piroxicam 相关分类

完整储备液配制表

* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 2 years; -20°C, 1 year。-80°C储存时，请在2年内使用， -20°C储存时，请在1年内使用。

可选溶剂 浓度 溶剂体积 质量 1 mg 5 mg 10 mg 25 mg
DMSO 1 mM 3.0180 mL 15.0898 mL 30.1796 mL 75.4489 mL
5 mM 0.6036 mL 3.0180 mL 6.0359 mL 15.0898 mL
10 mM 0.3018 mL 1.5090 mL 3.0180 mL 7.5449 mL
15 mM 0.2012 mL 1.0060 mL 2.0120 mL 5.0299 mL
20 mM 0.1509 mL 0.7545 mL 1.5090 mL 3.7724 mL
25 mM 0.1207 mL 0.6036 mL 1.2072 mL 3.0180 mL
30 mM 0.1006 mL 0.5030 mL 1.0060 mL 2.5150 mL
40 mM 0.0754 mL 0.3772 mL 0.7545 mL 1.8862 mL
50 mM 0.0604 mL 0.3018 mL 0.6036 mL 1.5090 mL
60 mM 0.0503 mL 0.2515 mL 0.5030 mL 1.2575 mL
80 mM 0.0377 mL 0.1886 mL 0.3772 mL 0.9431 mL
100 mM 0.0302 mL 0.1509 mL 0.3018 mL 0.7545 mL
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Piroxicam36322-90-4CP-16171吡罗昔康CP16171CP 16171COXCyclooxygenaseInhibitorinhibitorinhibit

您最近查看的产品:

Your information is safe with us. * Required Fields.

   产品名称：

  

* 需求量：

* 客户姓名：

 

* Email：

* 电话：

 

* 公司或机构名称：

   留言给我们：

Bulk Inquiry

Inquiry Information

产品名称：
Piroxicam
目录号：
HY-B0253
需求量：

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

   产品名称：

  

* Lot #：

* 客户姓名：

 

* Email：

   电话：

 

* 部门：

* 公司或机构名称：

 

   留言给我们：

Request for HNMR Report

We have received your request and will respond to you as soon as possible.

嗨！很高兴为您提供帮助！

尊敬的 MCE 客户您好，
请您选择所在区域，我们将转接对应客服为您服务！

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

热 A B C F G H J L N Q S T X Y Z